GE seeks U.S., EU approval of imaging agent 18F-flutemetamol

01/8/2013 | HealthImaging.com

GE Healthcare has submitted a new drug application to the FDA and a marketing authorization application to the European Medicines Agency for its PET imaging agent 18F-flutemetamol. Both applications seek approval for the use of the imaging agent in visualizing beta amyloid levels in the brains of adults being assessed for Alzheimer's disease.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care